Evaluation of the Effect of CYP2D6 and OCT1 Polymorphisms on the Pharmacokinetics of Tramadol: Implications for Clinical Safety and Dose Rationale in Paediatric Chronic Pain

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2024 Oct 9

PMID 39384340

Authors

Paul Healy

Karel Allegaert

Oscar Della Pasqua

Affiliations

Soon will be listed here.

Abstract

Aims: Our investigation aimed to assess the dose rationale of tramadol in paediatric patients considering the effect of CYP2D6/OCT1 polymorphisms on systemic exposure. Recommendations were made for the oral dose of tramadol to be used in a prospective study in children (3 months to < 18 years old) with chronic pain.

Methods: Intravenous pharmacokinetic and genotype data from neonatal patients (n = 46) were available for this analysis. The time course of tramadol and O-desmethyltramadol (M1) concentrations was characterized using a nonlinear mixed effects approach in conjunction with extrapolation principles. Clinical trial simulations were then implemented to explore the effects of polymorphism, maturation and developmental growth on the disposition of tramadol and M1. Reported efficacious exposure range in adult subjects were used as reference.

Results: The pharmacokinetics of tramadol and M1 was characterized by a two-compartment model. The total clearance of tramadol (CLPP) comprised CYP2D6-mediated metabolism (CLPM) and other pathways (CLPO). Age-related changes in CLPM, CLPO and M1 clearance (CLMO) were described by a sigmoid function, with CYP2D6 as a covariate on CLPP and CLPM, and OCT1 on CLMO. Simulation scenarios including different CYP2D6/OCT1 combinations revealed that steady-state concentrations are above the putative ranges for analgesia in >15% and >70% of subjects after doses of 3 and 8 mg/kg, respectively.

Conclusions: In the absence of genotyping, reference exposure ranges can be used to define the dose rationale for tramadol in paediatric chronic pain. However, a starting dose of 0.5 mg/kg/day should be considered, followed by stepwise titration to the desired analgesic response.

Citing Articles

Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain.

Healy P, Allegaert K, Della Pasqua O Br J Clin Pharmacol. 2024; 91(2):283-296.

PMID: 39384340 PMC: 11773095. DOI: 10.1111/bcp.16201.

References

Allegaert K, Anderson B, Verbesselt R, Debeer A, de Hoon J, Devlieger H . Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth. 2005; 95(2):231-9. DOI: 10.1093/bja/aei170. View

Ozkose Z, Akcabay M, Kemaloglu Y, Sezenler S . Relief of posttonsillectomy pain with low-dose tramadol given at induction of anesthesia in children. Int J Pediatr Otorhinolaryngol. 2000; 53(3):207-14. DOI: 10.1016/s0165-5876(00)82008-x. View

Tzvetkov M, Saadatmand A, Lotsch J, Tegeder I, Stingl J, Brockmoller J . Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011; 90(1):143-50. DOI: 10.1038/clpt.2011.56. View

de Leeuw T, Mangiarini L, Lundin R, Kaguelidou F, der Zanden T, Della Pasqua O . Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized.... Trials. 2019; 20(1):49. PMC: 6334401. DOI: 10.1186/s13063-018-3169-3. View

Stukas S, Cooper J, Higgins V, Holmes D, Adeli K, Wellington C . Pediatric reference intervals for serum neurofilament light and glial fibrillary acidic protein using the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) cohort. Clin Chem Lab Med. 2023; 62(4):698-705. PMC: 10895925. DOI: 10.1515/cclm-2023-0660. View

Eerdekens M, Beuter C, Lefeber C, van den Anker J . The challenge of developing pain medications for children: therapeutic needs and future perspectives. J Pain Res. 2019; 12:1649-1664. PMC: 6536714. DOI: 10.2147/JPR.S195788. View

Gong L, Stamer U, Tzvetkov M, Altman R, Klein T . PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014; 24(7):374-80. PMC: 4100774. DOI: 10.1097/FPC.0000000000000057. View

Orliaguet G, Hamza J, Couloigner V, Denoyelle F, Loriot M, Broly F . A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics. 2015; 135(3):e753-5. DOI: 10.1542/peds.2014-2673. View

Grond S, Meuser T, Uragg H, Stahlberg H, Lehmann K . Serum concentrations of tramadol enantiomers during patient-controlled analgesia. Br J Clin Pharmacol. 1999; 48(2):254-7. PMC: 2014292. DOI: 10.1046/j.1365-2125.1999.00986.x. View

10.

Stamer U, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A . Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003; 105(1-2):231-8. DOI: 10.1016/s0304-3959(03)00212-4. View

11.

Benini F, Barbi E . Doing without codeine: why and what are the alternatives?. Ital J Pediatr. 2014; 40(1):16. PMC: 3996141. DOI: 10.1186/1824-7288-40-16. View

12.

Healy P, Verrest L, Felisi M, Ceci A, Della Pasqua O . Dose rationale for gabapentin and tramadol in pediatric patients with chronic pain. Pharmacol Res Perspect. 2023; 11(5):e01138. PMC: 10558965. DOI: 10.1002/prp2.1138. View

13.

Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder J . Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2016; 19(1):69-76. PMC: 5292679. DOI: 10.1038/gim.2016.80. View

14.

Ceci A, Giaquinto C, Aboulker J, Baiardi P, Bonifazi F, Della Pasqua O . The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence. Paediatr Drugs. 2009; 11(1):18-21. DOI: 10.2165/0148581-200911010-00008. View

15.

Dyderski S, Szkutnik D, Zgrabczynska M, Drobnik L . Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. Acta Pol Pharm. 2002; 58(5):345-9. View

16.

Borella E, Oosterholt S, Magni P, Della Pasqua O . Characterisation of individual ferritin response in patients receiving chelation therapy. Br J Clin Pharmacol. 2022; 88(8):3683-3694. PMC: 9544664. DOI: 10.1111/bcp.15290. View

17.

Kaguelidou F, Le Roux E, Mangiarini L, Lundin R, de Leeuw T, Della Pasqua O . Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol. BMJ Open. 2019; 9(2):e023296. PMC: 6398794. DOI: 10.1136/bmjopen-2018-023296. View

18.

Ogawa K, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H . Occupancy of serotonin transporter by tramadol: a positron emission tomography study with [11C]DASB. Int J Neuropsychopharmacol. 2014; 17(6):845-50. DOI: 10.1017/S1461145713001764. View

19.

Crews K, Monte A, Huddart R, Caudle K, Kharasch E, Gaedigk A . Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021; 110(4):888-896. PMC: 8249478. DOI: 10.1002/cpt.2149. View

20.

Healy P, Allegaert K, Della Pasqua O . Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain. Br J Clin Pharmacol. 2024; 91(2):283-296. PMC: 11773095. DOI: 10.1111/bcp.16201. View